AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$PACS

Murray Jason Hulse sold $2.2M of PACS

Murray Jason Hulse (Co-Founder, CEO & Chairman) sold 51,887 shares of PACS Group, Inc. (PACS) at an average of $43.12 ($42.68–$43.59, $2.24M total) across 5 trades over 2026-09-04 to 2026-09-09 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Murray Jason Hulse
Published Sep 9, 2026, 9:38 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 9, 2026, 9:57 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$PACS
Neutral
medium confidence
Mentioned
$PACS
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PACSNeutralLow
01

Why it matters

The disclosed sale provides fresh data on insider sentiment for PACS.

02

Market read

Insider sales are monitored by traders; this filing adds a new data point for PACS.

03

What to watch

The 10b5-1 plan pre‑arranged nature may mitigate negative interpretation.

Relevance 5/10Novelty 7/10Timing: filing today

Background

Form 4 filing discloses insider transactions required by the SEC.

Company-level read

Ticker impact

$PACSNeutralMedium confidence
Context

CEO Murray Jason Hulse sold 51,887 shares for $2.2M via a 10b5-1 plan, reducing his stake in PACS.

Expected impact

Potential short-term pressure on PACS stock, likely limited to a few percent.

Evidence & confidence

A $2.2M sale by the CEO is material but not large enough to drive a major move; market may view it as routine execution of a pre‑arranged plan.

Market effects

Sector

Minimal impact on the broader medical device sector.

Regional

Limited to U.S. investors tracking PACS.

Global

Low

Counterpoint

What could challenge this read

The sale could be a routine liquidity event, not a negative signal.

Key entities

  • person
    Murray Jason Hulse

    Co‑Founder, CEO & Chairman of PACS

  • company
    PACS Group, Inc.

    Medical device company listed on Nasdaq under ticker PACS

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

PACS insider trading history →

Related articles

$PACSMedAI 8/10

What PACS Group (PACS) Said on Its Q3 Earnings Call

PACS Group reported 196 mature, 90 ramping, and 35 new skilled nursing facilities with occupancy ranging from 76.2% to 93.1%. The company acquired 32 Florida and 10 Texas skilled nursing operations post-quarter. PACS raised its 2026 revenue outlook to $5.95B-$6.05B and adjusted EBITDA to $685M-$695M, citing strength in existing operations and new acquisitions. Operating cash flow was $583.1M for the first nine months of 2026, with $707.4M in available liquidity.

finance.yahoo.com
$PACSHighAI 8/10

PACS Group Inc (PACS) (Q3 2026) Earnings Call Highlights: Revenue Tops

PACS Group Inc (NYSE:PACS) reported Q3 2026 revenue growth of 6.4%, with adjusted EBITDA up 33.6% to $175.7M. The company raised full-year guidance, citing strong occupancy and skilled mix improvements. PACS also highlighted a robust acquisition pipeline and integration plans for 31 Eduro facilities. Challenges include lower metrics at newly acquired facilities and ongoing government investigations.

finance.yahoo.com
$PACSHigh

Why is PACS stock surging today?

PACS Group Inc (PACS) stock rose 6.0% in after-hours trading after beating Q3 2026 earnings and revenue estimates. The company also raised its full-year 2026 Adjusted EBITDA and revenue guidance. Analysts maintain a 'Moderate Buy' rating with an average price target of $58.80. The surge was driven by company-specific news.

investing.com